Nuwellis (NUWE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for May 20, 2025, as a virtual event, with stockholders able to vote and ask questions online.
Four main proposals are up for vote: election of two directors, approval of a reverse stock split, ratification of the auditor, and authorization to adjourn if needed.
The board unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors for three-year terms.
Proposal 2: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-70, at the board's discretion, to maintain Nasdaq listing.
Proposal 3: Ratify Baker Tilly US, LLP as independent auditor for 2025.
Proposal 4: Authorize adjournment of the meeting to solicit more proxies if Proposal 2 lacks sufficient votes.
Board of directors and corporate governance
The board consists of six members with staggered three-year terms; two Class III directors are up for re-election.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
The board has adopted updated insider trading and corporate governance policies, and conducts annual performance evaluations.
Board diversity is tracked and disclosed, with a mix of gender and professional backgrounds.
Latest events from Nuwellis
- Q4 revenue and margin gains, strategic moves, and new leadership set up 2026 growth.NUWE
Q4 202520 Mar 2026 - Innovative fluid management platform targets $4.2B market with strong clinical and financial momentum.NUWE
Investor presentation10 Mar 2026 - Registering 4.28M shares for resale, proceeds from warrant exercises support working capital.NUWE
Registration Filing4 Feb 2026 - Q2 revenue up 6% to $2.2M, gross margin 67.2%, but cash runway and losses remain concerns.NUWE
Q2 20241 Feb 2026 - Q3 net income reached $2.4M, with improved margins and major reimbursement gains set for 2025.NUWE
Q3 202415 Jan 2026 - Improved margins and CMS reimbursement set stage for outpatient growth despite lower Q4 revenue.NUWE
Q4 202425 Dec 2025 - Flexible $25M shelf offering targets R&D and growth in fluid management devices.NUWE
Registration Filing16 Dec 2025 - Proxy seeks approval for director elections, reverse split, and auditor ratification to ensure compliance.NUWE
Proxy Filing2 Dec 2025 - Key votes include warrant share issuance, share increase, and reverse split for Nasdaq compliance.NUWE
Proxy Filing2 Dec 2025